Investors in Pennsylvania-based AmerisourceBergen Corp. have sued in Delaware for access to books and records of the pharmaceutical firm, stating that they are considering launching a civil lawsuit over a scheme by its subsidiaries to skim and repackage cancer drugs for sale across the country.

A Minnesota-based pension fund on Tuesday filed a complaint saying there was “more than a credible basis” to believe Amerisource’s leadership was aware of a longstanding practice at its two divisions in Alabama, which resulted in $885 million in criminal and civil fines, as well as “untold reputational harm.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]